Biotechnology company Ascletis Pharma Inc (HKEX:1672) announced on Wednesday that preclinical data of ASC36_35 FDC, a once-monthly injection co-formulation of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist, for the treatment of obesity, will be presented in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting being held in Milan, Italy.
According to the company, the data demonstrate superior weight loss to the eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model.
The presentation is scheduled for 14:00 - 15:00 CEST on Thursday, 1 October 2026.
ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC once-monthly co-formulation is Self-Assembling Lipid Depot (SALD) formulation, developed in-house utilising Ascletis' Ultra-Long-Acting Platform (ULAP) technology.
Bayer completes acquisition of Perfuse Therapeutics to strengthen ophthalmology pipeline
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
Tandem Diabetes Care receives CE mark for expanded automated insulin delivery indications in Europe
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Samsung Bioepis launches OPUVIZ across Europe for ophthalmic conditions
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany